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Background and Aims 
Limited data are available to investigate the impact of index adenoma size on the risk of 
metachronous advanced adenomas. Our goal was to examine the impact of having small (5-9 
mm) versus diminutive (<5 mm) adenomas on the future risk of advanced adenomas within the
categories for polyps <1cm currently used in the United States: 1 to 2 and 3 or more tubular
adenomas.
Methods
We included data from individuals participating in the statewide, population-based New
Hampshire Colonoscopy Registry (NHCR). Groups were based on index findings: (1) 1 to 2
adenomas <5 mm (both diminutive), (2) 1 to 2 adenomas <1 cm (one or both small), (3) 3 to 10
adenomas <5 mm (all diminutive), (4) 3 to 10 adenomas <1 cm (one or more small), and (5)
advanced adenomas (AA). AAs were defined as adenomas >1cm or those with villous elements
or high-grade dysplasia and colorectal cancer (CRC). Outcomes were the absolute and adjusted
risk of metachronous advanced adenomas. Covariates included age, sex, body mass index, family
history of CRC, lifestyle factors, presence of serrated polyps, and time since the index
examination.
Results
After adjusting for the covariates, we observed that having 1 to 2 adenomas with at least one 5 to
9 mm adenoma (adjusted odds ratio [AOR], 1.54; 95% CI, 1.12-2.11), 3 to 10 diminutive
adenomas (AOR, 1.75; 95% CI, 1.03-2.95), 3 to 10 adenomas <1 cm (1 or more small) (AOR,
2.14; 95% CI, 1.39-3.29) or advanced adenomas (AOR, 2.77; 95% CI, 2.05-3.74) were
associated with an increased risk for metachronous AA as compared with having 1 to 2
diminutive adenomas. A further stratification of Group 2 observed that those with exactly 2
small adenomas had an absolute risk of future AA of 7.6% (11/144) (95% CI, 4.3%-13.2%),
higher than the absolute risk in the 1 to 2 diminutive polyp group, and similar to the risk for 3 to
10 adenomas 8.2 (95% CI, 5.4-11.9).
Conclusions
For individuals with 1 to 2 adenomas <1 cm, having at least 1 small adenoma increased the
metachronous risk of AA compared to having only diminutive adenomas. Furthermore, the
subset with 2 small adenomas had a risk of future AA similar to the risk for 3 to 10 adenomas.
These data suggest that individuals with at least 1 small adenoma may be at higher risk for future
advanced adenomas and thus require closer follow-up than those with only diminutive
adenomas. These data may be valuable to guideline committees for the creation of future
surveillance recommendations.
Background 
Colorectal cancer (CRC) is the second most common cause of death from cancer in the 
United States1, despite being a preventable disease. The key to prevention lies in delivery of 
appropriate and timely screening and surveillance colonoscopies, and development of 
appropriate guideline recommendations for prevention requires evidence to inform those 
guidelines. Colonoscopy is the most common form of CRC screening in the United States, and 
surveillance colonoscopies, which are follow-up colonoscopies in individuals found to have 
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potentially precancerous polyps or CRC, account for about 3 million examinations annually in 
the United States2, 3. Therefore, evidence to support surveillance guidelines is essential to 
effective CRC prevention and early detection.   
The current US guideline recommendation for surveillance intervals for individuals with 
only 1 to 2 diminutive and small (ie, <1 cm) tubular adenomas is to have a repeat colonoscopy in 
5 to 10 years4, 5. Small and diminutive (<1 cm) tubular adenomas are a common finding on 
colonoscopy, and there has been a debate regarding the appropriate surveillance intervals for 
individuals with these polyps. A few long-term studies suggest that individuals with 1 to 2 
tubular adenomas <1 cm are at a low risk for CRC,6-8 and thus these lesions are referred to as 
low-risk adenomas (LRA). However, long-term studies may be limited by low numbers of CRC 
as well as the analytic challenge of accounting for the impact of surveillance examinations when 
comparing the risk for individuals with low-risk adenomas with those with no adenomas 6, 7. 
Although preventing CRC is the primary aim of CRC screening and surveillance through 
colonoscopy, evidence to inform guidelines is often based on the risk of metachronous advanced 
adenomas, which are more commonly detected and are often used as a surrogate outcome for 
CRC9-12. Thus, data examining metachronous risk for advanced adenomas are useful in 
investigating clinical management issues for individuals with index adenomas ≤1 cm. 
One issue that should be addressed is whether recommendations for adults with only 
diminutive tubular adenomas detected at colonoscopy should parallel recommendations for 
individuals with small tubular adenomas. For example, it is unclear whether 1 to 2 diminutive 
(<5 mm) adenomas are associated with the same level of risk posed by having 1 to 2 small (6-9 
mm) adenomas, and evidence to illuminate this question is lacking. Since index adenoma size 
has been shown to be an important predictor for metachronous advanced adenomas, it has been 
postulated that further risk stratification of individuals with index diminutive and small 
adenomas may improve CRC surveillance11, 13. The size of small adenomas has been shown to be 
an important predictor of future neoplasia for individuals with non advanced11 and advanced 
adenomas12. Current U.S. Multi-Society on Colorectal Cancer surveillance guidelines 
recommend that individuals with 1 to 2 adenomas <1 cm return for surveillance colonoscopy in 5 
to 10 years; and that individuals with >3 adenomas, or at least one adenoma >1cm, considered to 
be at higher risk, have a surveillance examination in 3 years4. Further stratifying the current risk 
category of 1 to 2 adenomas <1 cm into those with small versus diminutive index adenomas may 
help identify individuals currently considered low risk who may actually be at higher risk for 
metachronous advanced adenomas.  
Our goal in the current analysis was to determine whether diminutive and small 
adenomas are associated with equivalent levels of risk. Specifically, we investigated the 
metachronous risk of advanced adenomas for individuals having at least 1 small (5-9 mm) 
tubular adenoma compared with those having all diminutive (<5 mm) tubular adenomas within 
the categories for polyps <1cm currently used in the United States: 1 to 2 and 3 or more small 
tubular adenomas. 
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Methods 
Population 
The New Hampshire Colonoscopy Registry (NHCR), described in detail elsewhere, was 
founded in 2004 as a population-based, statewide registry collecting data from endoscopy sites 
throughout New Hampshire (NH) 14-16. Prior to colonoscopy, consenting patients complete a self-
administered patient questionnaire which collects data on demographic factors (e.g. age, sex, 
marital status, education), health behaviors (e.g.  smoking, alcohol intake, aspirin use and 
exercise), and detailed family and personal history of polyps and CRC.  
 Endoscopists complete the NHCR procedure form immediately after the exam has been 
completed. The endoscopist may personally complete form or communicate information to the 
endoscopy nurse assisting with the colonoscopy. Data collected include detailed indication for 
the exam, findings (location, size and specific treatment of polyps, cancer, or other findings), 
type and quality of bowel preparation, sedation medication, anatomical location reached during 
the procedure, withdrawal time, follow-up recommendations, and immediate complications. Size 
is recorded as per the endoscopist’s measurement and is categorized as < 5 mm, 5-9 mm and 
 > 10 mm.  
The NHCR requests pathology reports for all colonoscopies with findings directly from 
the pathology laboratory used by each participating endoscopy facility. Trained NHCR staff 
abstract and enter these pathology findings, including location, size, and histology of each polyp, 
into the NHCR database, matching individual polyp level pathology data to information from the 
colonoscopy procedure form.16 All data collection and study procedures were approved by the 
Committee for the Protection of Human Subjects at Dartmouth College (study # 00015834), as 
well as by other relevant human subjects reviewing bodies at participating sites. 
Cohort 
We included individuals with index adenomas and a follow up colonoscopy at least one 
year after index exam in the NHCR. Exams with poor bowel preparation or incomplete exams 
and individuals with familial syndromes or IBD were excluded.  
Covariates 
The covariates examined were patient age, sex, body mass index (BMI), family history of 
CRC (defined as at least one first-degree relative with CRC), previous colorectal neoplasia, 
aspirin use (none versus at least once per week), educational level (high school or more), 
exercise (never versus at least once per week), and alcohol intake (>5 versus <5 servings per 
week). Presence at index colonoscopy of clinically significant serrated polyps (CSSPs, including 
all SSA/Ps, TSAs, HPs >1 cm anywhere in the colon or any HP > 5mm in the proximal colon) 
was also a covariate. Endoscopist Adenoma Detection Rate (ADR) was assessed at both index 
and surveillance colonoscopy. All variables were considered categorical except for age, BMI, 
ADR, and months since index exam, which were continuous variables. 
Exposure variable 
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Individuals were divided into 5 groups based on index findings: Group 1) 1-2 diminutive 
tubular adenomas (< 5 mm), Group 2) 1-2 tubular adenomas < 1cm (one or both small (5-9 mm), 
Group 3) 3-10 diminutive tubular adenomas (< 5 mm), Group 4) 3-10 tubular adenomas (< 1 cm) 
(one or more small) and Group 5) advanced adenomas (AA). AAs were defined as adenomas 
>1cm or those with villous elements, high-grade dysplasia, or CRC.  
Statistical approach 
Outcomes were the absolute and adjusted risk of metachronous AAs. Covariates in the 
multivariable analysis included age (continuous), sex, BMI (continuous), family history of CRC, 
smoking (never, past or current), alcohol intake, education, exercise, presence of CSSPs, months 
(continuous) since index exam as well as co-variates listed above. 
Results 
There were 6876 adults in the NHCR database with two exams at least one year apart 
with at least one adenoma at index exam. After excluding both index and follow-up exams which 
were incomplete (n=199), or had poor bowel preparation (n=456), and patients with IBD (n=77) 
or familial colorectal cancer syndromes (n=61), 6083 individuals remained in the sample. These 
patients were stratified by index findings into: Group 1) 1-2 diminutive adenomas (n=2568), 
Group 2) 1-2 tubular adenomas (at least one small) (n=1294), Group 3) 3-10 diminutive 
adenomas (n=293), Group 4) 3-10 tubular adenomas (one or more small) (n=425) and Group 5) 
advanced adenomas (n= 1503). Characteristics for these groups including age, sex, BMI, lifestyle 
factors, synchronous serrated polyps and months to follow up are shown in Table 1. 
The absolute risks for metachronous advanced adenomas are shown in Table 2. After 
adjusting for the covariates, we observed that having 1-2 adenomas at least one of which was 
small (5-9 mm) was associated with an increased risk for metachronous AA as compared to 
having 1-2 diminutive adenomas (Table 2). However, the metachronous risk for individuals with 
3-10 adenomas that were all diminutive was similar to those with 3-10 adenomas < 1cm, at least 
one of which was small. A further stratification of Group 2 observed that those with exactly 2 
small adenomas had an absolute risk of future AA of 7.6% (11/144) (95% CI; 4.3-13.2%), higher 
than the absolute risk in the 1-2 diminutive polyp group, and similar to the risk for 3-10 
adenomas 8.2 (95%: 5.4-11.9). The risks associated with each co-variate are shown in Table 3.  
To examine the impact of time between index and surveillance colonoscopy on risk of 
metachronous findings at subsequent colonoscopy, we performed a sensitivity analysis in which 
we restricted the cohort to those with surveillance colonoscopy at least 3 years after index exam. 
The results were similar and are shown in Table 4. 
 
Discussion 
Our analysis showed that all adenomas < 1 cm may not be associated with equal risks; 
rather, the specific size of index tubular adenomas <1cm was important and positively modified 
the risk for metachronous advanced adenomas in adults with “low risk” adenomas. Specifically, 
we observed that individuals with 1-2 adenomas < 1 cm, at least one of which was small (5-9 
mm), had an increased metachronous risk of advanced adenomas as compared to those with 1-2 
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diminutive (< 5 mm) adenomas. Furthermore, a subset of Group 2 with 2 adenomas, both of 
which were small, had a risk of future advanced adenomas similar to that in patients with 3-10 
adenomas <1 cm. In adults with 3-10 adenomas < 1cm, there was no increased risk observed 
with having at least one small versus having all diminutive adenomas. 
A 2014 meta-analysis demonstrated that individuals with low risk adenomas (1-2 small 
tubular adenomas) had a higher rate of metachronous adenomas than those with no adenomas on 
index exam17. However, the absolute risk for metachronous adenoma was low in both groups: 
1.6% for the no adenoma group and 3.6% for the low risk adenoma group. Some studies have 
attempted to use index adenoma size to stratify adults with small adenomas into those at high and 
low risk for metachronous advanced adenoma. One such study from South Korea showed that 
adults with 3-10 diminutive tubular adenomas did not have an increased risk for metachronous 
advanced colorectal neoplasia as compared to the reference group, having 1-2 small adenomas 
on index colonoscopy10. Conversely those with advanced adenoma or 3-10 adenomas and at least 
3 small tubular adenomas had an increased risk. In our analysis, adults with 3-10 adenomas < 
1cm, there was no increased risk observed with having at least one small versus having all 
diminutive adenomas. 
A more recent study from South Korea divided individuals with index adenomas into 4 
groups, those with: 1-2 non-advanced adenomas;  ≥3 non-advanced, diminutive (1 to 5 mm) 
adenomas; ≥3 non-advanced, small (6–9 mm) adenomas; and advanced adenomas9. They 
observed that those with ≥ 3 non-advanced diminutive adenomas had a borderline increased risk 
of metachronous advanced adenomas compared with patients with 1-2 small tubular adenomas, 
suggesting that size (small versus diminutive) may be an important modifier for multiple 
adenomas. One limitation of this study is that the median follow up for the low risk adenoma 
group (38 months) was shorter than the recommended interval of 5-10 years. One possible 
consequence, as suggested by an accompanying editorial, was that metachronous risk may have 
been underestimated in the low risk group18. The follow up time between index and surveillance 
colonoscopy for our study was more consistent with current guidelines. For example, the mean 
follow up for those with 1-2 adenomas was close to 60 months (5 years) while that for patients 
with ≥3 advanced adenomas was closer to 36 months (3 years). In addition, we performed a 
sensitivity analysis excluding those with the shortest follow-up intervals (1-3 years) and 
observed similar results. 
The data presented here support the recommendation that individuals with 1-2 diminutive 
adenomas are at low risk for metachronous advanced adenomas, and current surveillance 
guideline recommendations of 5-10 year follow up are appropriate. We also observed a 
statistically significant increased risk for metachronous advanced adenomas for those individuals 
with ≥3 adenomas, regardless of size, and for those with advanced adenomas. These data support 
the close follow up suggested in the guidelines. Our analyses also demonstrated a statistically 
significant increase for metachronous advanced adenomas in those individuals with 1-2 
adenomas, at least one of which is small, as compared to those with 1-2 diminutive adenomas. 
Thus, our data suggest that shorter surveillance intervals may be appropriate for adults with 1-2 
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adenomas <1 cm, at least one of which is small, as compared to our reference group with 1-2 
diminutive adenomas. Furthermore, a subgroup with 2 adenomas, both of which were small, had 
a higher risk of metachronous advanced adenomas that was similar to the risk for those with ≥3 
adenomas, supporting the suggestion that individuals in this group may require closer follow up 
than those with diminutive adenomas only. 
Strengths of this analysis included the incorporation of several known CRC risk factors 
as covariates, including BMI, family history, smoking and other lifestyle factors such as alcohol 
intake. A recent editorial suggested that endoscopists routinely adjust for these important factors 
when measuring their own adenoma detection rates for quality purposes18. Our analysis also 
adjusted for the impact of clinically significant serrated polyps detected at index colonoscopy. In 
addition, we accounted for follow up time, which did not impact our results. Finally, since much 
of the data regarding impact of size is published from Korea, our data provide novel information 
using a different population, in addition to analysis of different multiplicity and size categories.  
One limitation of this study is that the cohort lacks racial diversity and is predominantly 
white, which limits generalizability. Although New Hampshire does not have significant racial 
diversity, there is considerable ethnic, urban/rural and socioeconomic diversity in the population 
that is captured within the NHCR19. However, the results should be confirmed in other patient 
populations. Another limitation is that the polyp sizes were based on the endoscopist’s visual 
estimate. While it is well known that endoscopic estimates of polyp size may be inaccurate and 
can vary in both directions (too large and too small),20, 21 this is currently the most widely 
utilized form of assessment and the method that guidelines assume endoscopists use to measure 
polyp size . Therefore, we used the endoscopist’s measurement of polyp size for our analyses. 
Furthermore, the specified ranges for size categories used on NHCR data collection forms for 
size categories used on NHCR data collection forms may help to ensure appropriate distinctions 
between diminutive, small, and large polyps. It should be acknowledged that the prospective 
cohort design as compared to a controlled trial may be limited with regard to possible 
confounding factors. However, our analysis is similar to that used in the studies cited above9, 10 
as well as other studies examining metachronous risk22, 23. Furthermore, we adjusted for many 
known CRC risk factors, decreasing the potential that confounding factors may have influenced 
the results. 
In summary, NHCR participants with 1-2 diminutive adenomas had a low risk for 
metachronous advanced adenomas, and these individuals may not require closer surveillance 
than currently recommended; extending to ten years may be an appropriate follow-up interval for 
this group. However, patients with 1-2 adenomas including at least one small adenoma appear to 
be at increased risk for future advanced adenomas compared to the group with only diminutive 
adenomas. These data can inform future surveillance guidelines. 
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Table 1. Patient and exam characteristics, stratified by index findings  
Factors 
Index Colonoscopy Findings  
Group 1 
1-2 
diminutive* 
adenomas 
Group 2 
1-2 adenomas 
< 1 cm, one or 
more small** 
Group 3 
3-10 diminutive* 
adenomas 
Group 4 
3-10 adenomas 
< 1 cm, one or 
more small** 
Group 5 
Advanced 
adenoma*** 
N 2568 1294 293 425 1503 
Age (mean + S.D.) 59.1 + 8.9 58.7 + 9.5 62.5 + 8.9 62.5 + 9.1 60.0 + 9.7 
Sex (% male) 1387 (54.0%) 
744 
(57.5%) 
204 
(69.6%) 
309 
(72.7%) 
890 
(59.2%) 
BMI 28.5 + 5.9 28.6 + 6.1 29.7 + 6.7 29.9 + 5.8 29.2 + 6.1 
Family history of CRC 
(first degree relative) 
617 
(24.0%) 
305 
(23.6%) 
68 
(23.2%) 
92 
(21.6%) 
313 
(20.8%) 
Current smokers 239 (9.9%) 
135 
(10.17%) 
39 
(13.5%) 
46 
(11.2%) 
211 
(14.5%) 
Aspirin use (regular) 995 (38.7%) 
536 
(41.4%) 
115 
(39.2%) 
217 
(51.1%) 
556 
(37.0%) 
Alcohol (at least 5 
drinks per week) 
804 
(31.3%) 
384 
(29.7%) 
104 
(35.5%) 
129 
(30.4%) 
448 
(29.8%) 
Education (HS or 
more) 
2383 
(92.8%) 
1207 
(93.3%) 
272 
(92.8%) 
389 
(91.5%) 
1379 
(91.7%) 
Regular exercise (at 
least 1/week) 
1444 
(56.2%) 
699 
(54.0%) 
145 
(49.5%) 
217 
(51.1%) 
742 
(49.4%) 
Previous adenomas 795 (31.5) 
388 
(30.6%) 
135 
(48.0%) 
197 
(47.7%) 
397 
(27.0%) 
Clinically significant 
serrated polyps**** at 
index exam 
190 
(7.5%) 
138 
(10.8%) 
22 
(7.6%) 
42 
(9.9%) 
149 
(11.3%) 
Months to surveillance 
exam 
57.9 + 19.2 56.7 + 12.1 42.5 + 15.1 40.6 + 16.0 38.6 + 23.0 
*Diminutive = <5 mm; **Small = 5-9 mm;  
*** Advanced adenomas: adenomas >1cm or those with villous elements, high-grade dysplasia, or CRC.  
**** Clinically Significant serrated polyps: all SSA/Ps, TSAs, HPs >1 cm anywhere in the colon or any HP 
> 5mm in the proximal colon 
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Table 2. The absolute risk, odds ratio (OR) and adjusted OR* for metachronous advanced adenomas 
in individuals with index adenomas as classified by current guideline categories, stratified by adenoma 
size 
Index findings N 
Absolute risk 
(%)  
(95% CI) 
Unadjusted OR (95% CI) *Adjusted OR (95% CI) P value 
1-2 diminutive 
adenomas  2568 
4.0 (3.2-4.8)  
(n=103) Reference (1.0) 1.0 Reference --- 
1-2 adenomas < 
1cm**  
(one or more 
small) 
1294 5.9 (4.7-7.3)  (n=76) 1.49 (1.10-2.02) 1.54 (1.12-2.11) 0.008 
3-10 diminutive 
adenomas 293 
8.2 (5.4-11.9) 
(n=24) 2.14 (1.35-3.39) 1.75 (1.03-2.95) 0.03 
3-10 adenomas 
< 1cm  
(one or more 
small) 
425 9.4 (6.4-11.9) (n=40) 2.49 (1.70-3.64) 2.14 (1.39-3.29) 0.001 
Advanced 
adenoma*** 1503 
10.0 (9.2-
12.2)  
(n=150) 
2.65 (2.05-3.44) 2.77 (2.05-3.74) 0.0001 
*Adjusted for age, sex, BMI, family history of CRC, smoking, presence or serrated polyps and years 
since index exam.  
** Subset of Group 2 of adults with 2 small adenomas (versus 1 or more small) absolute risk: 7.3% 
(95% CI; 5.0-10.4%) 
*** Advanced adenomas: adenomas >1cm or those with villous elements, high-grade dysplasia, or CRC.  
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Table 3 Co-variate factors’ unadjusted and adjusted risks for advanced adenoma on surveillance 
exam 
Factor Unadjusted OR (95% CI) Adjusted OR (95% CI) 
Age (per year) 1.03 (1.02-1.04) 1.02 (1.02-1.04) 
Sex (male reference) 0.76 (0.62-0.94) 0.87 (0.68-1.11) 
BMI 1.02 (1.00-1.04) 1.02 (1.00-1.04) 
Family history of CRC (FDR) 
(none reference) 1.18 (0.93-1.49) 1.18 (0.91-1.53) 
Current smokers (never 
reference) 1.28 (0.91-1.78) 1.13 (0.77-1.65) 
Past (never reference) 1.17 (0.93-1.46) 1.02 (0.80-1.30) 
Previous adenomas 
(none reference) 1.50 (1.22-1.86) 1.28 (1.00-1.63) 
Aspirin use (regular use) 
(none reference) 1.25 (1.02-1.53) 1.08 (0.85-1.36) 
Alcohol use (at least 5 drinks 
per week) 
(< 5 reference) 
0.93 (0.74-1.16) 1.00 (0.78-1.28) 
Education (HS or more versus 
lower level) 0.81 (0.57-1.16) 0.90 (0.57-1.43) 
Regular exercise (at least 
1/week) (none reference) 0.74 (0.60-0.91) 0.88 (0.70-1.11) 
Clinically significant serrated 
polyps at index (none 
reference) 
1.55 (1.13-2.12) 1.44 (1.02-2.04) 
ADR of endoscopist who 
completed index colonoscopy 1.00 (0.99-1.01) 0.99 (0.98-1.01) 
ADR of endoscopist who 
conducted surveillance 
colonoscopy 
1.00 (1.00-1.01) 1.01 (1.00-1.02) 
Months to surveillance exam 1.00 (0.99-1.00) 1.01 (1.00-1.01) 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 4. The absolute and adjusted risk* for metachronous advanced adenomas in individuals with 
index adenomas as classified by current guideline categories, stratified by adenoma size, in patients 
with at least 36 months between index and surveillance colonoscopy 
Index findings Follow up time  (mean months + S.D.) *Adjusted Risk (95% CI) P value 
1-2 adenomas < 5 mm  
(both diminutive) 62.0 + 16.0 1.0 Reference --- 
1-2 adenomas < 1cm**  
(one or more small) 61.1 + 18.2 1.51 (1.08-2.09) 0.01 
3-10 adenomas < 5 mm 
(all diminutive) 47.1 + 13.0 1.72 (1.01-2.95) 0.05 
3-10 adenomas < 1cm  
(one or more small) 47.4 + 13.5 2.00 (1.25-3.18) 0.004 
Advanced adenoma 53.9 + 20.5 2.53 (1.82-3.53) 0.0001 
*Adjusted for age, sex, BMI, family history of CRC, smoking, presence or serrated polyps and years 
since index exam.   
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Abbreviations and Acronyms 
Adenoma detection rate: ADR 
Serrated polyp detection rate: SDR 
Sessile serrated adenomas/polyps: SSA/P  
Traditional serrated adenomas: TSA 
 Hyperplastic polyps: HP 
New Hampshire Colonoscopy Registry: NHCR 
American College of Gastroenterology: ACG 
American Society for Gastrointestinal Endoscopy: ASGE 
Colorectal Cancer: CRC 
Body Mass Index: BMI 
Inflammatory bowel disease: IBD 
Low risk adenoma: LRA 
High risk adenoma: HRA 
US Multi Society Task Force 
Clinically significant serrated polyps: CSSPs 
High grade dysplasia: HGD 
High school: HS 
 
